Free press releases distribution network?

More news: Health/Surgery
Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Changes in Reimbursement Structure to Aid Greater Adoption of Brachytherapy - New analysis from Frost & Sullivan, U.S. Brachytherapy Markets, reveals that the market achieved revenue worth $157.6 million in 2004 and estimates to reach $300.2 million in 2010.
Changes in Reimbursement Structure to Aid Greater Adoption of Brachytherapy

 

PRZOOM - /newswire/ - San Antonio, TX, United States, 2005/04/20 - New analysis from Frost & Sullivan, U.S. Brachytherapy Markets, reveals that the market achieved revenue worth $157.6 million in 2004 and estimates to reach $300.2 million in 2010..

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Traditionally, urologists are resistant to refer prostate cancer patients to radiation oncologists because they are either deterred by the technical complexity of brachytherapy procedures or prefer to perform prostatectomies due to their lucrative payments. However, reduced reimbursement for external beam and intensity modulated radiation therapy (IMRT) is likely to compel physicians to consider brachytherapy treatment options for their higher payments.

New analysis from Frost & Sullivan, U.S. Brachytherapy Markets, reveals that the market achieved revenue worth $157.6 million in 2004 and estimates to reach $300.2 million in 2010.

If you are interested in a virtual brochure, which provides manufacturers, end-users and other industry participants an overview of the latest analysis of the U.S. Brachytherapy Markets - then send an email to Danielle White - Corporate Communications at dwhite[.]frost.com with the following information: your full name, company name, title, telephone number, fax number, and email. Upon receipt of the above information, an overview will be sent to you via e-mail.

Centers for Medicare & Medicaid Services (CMS) have made many modifications to reimbursement payment structure for implantable seeds. The Medicare Prescription Drug, Improvement and Modernization Act of 2003 has also provided for separate payments for brachytherapy seeds.

“These policies eliminate restrictive monetary caps on brachytherapy seed reimbursement,” states Frost & Sullivan Research Analyst Sheila Ewing. “It enables physicians to decide the seed type, number of seeds, and advanced seed technologies, thereby reducing concern regarding reimbursement restrictions.”

While altering payment structure has helped stave off challenge from prostatectomies, alternative technologies such as hormone therapy or gene modification are posing new threats to brachytherapy. The market is also likely to be challenged by the slow growth in patient population.

Manufacturers promoting recently released positive long-term data results for seed implants can ease friction cased by these market restraints. Several favorable long-term studies on prostate and breast cancer therapies using brachytherapy and most of the results have been favorable. are opening the door for other cancer applications.

“More than 15 years of clinical trial results for brachytherapy drives acceptance in prostate cancer treatment,” observes Ewing. “However, limited data is available for usage of brachytherapy in the treatment of head, neck, and other cancers.”

The largest patient study of prostate brachytherapy primarily using Theragenics Corporation’s palladium seeds demonstrated a cancer-death rate of 81 percent. A 15-year clinical trial by Oncura, exclusively using its OncoSeed, results indicated after a five-year follow-up that 93 percent of patients remained cancer death. Meanwhile, Proxima Therapeutics, Inc.’s 3-year study using its MammoSite Radiation Therapy System (RTS) device for breast cancer, found no local recurrences.

These clinical trials open up markets with opportunities in new applications. Manufacturers that are ahead of their counterparts in providing positive clinical trials for additional cancer applications are anticipated to lead the market in revenue and shares.

“The studies provide critical evidence needed by physicians regarding the effectiveness of brachytherapy for treatment of prostate and breast cancer, and are expected to encourage brachytherapy procedures,” notes Ewing.

Greater opportunities for brachytherapy are expected, especially with the U.S. Congress’ resolution encouraging physicians to inform prostate cancer patients of all proven treatments available and use of prostate-specific antigen (PSA) and mammogram tests for early detection of cancer.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


Changes in Reimbursement Structure to Aid Greater Adoption of Brachytherapy

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Danielle White 
210-247-2403
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Health/Surgery Most Recent Related Press Releases:

Sustainable Alternatives to Polyvinylidene Chloride-coated Films Create Growth Opportunities & Transform the Food Packaging Markets in Western Europe
RIKEN Biofunctional Synthetic Chemistry Laboratory in Japan Has Developed A Way to Engineer Glycan Complexes Clusters of Sugar Chains
The Clinicians of Longs Peak Emergency Physicians Join US Acute Care Solutions
Frost & Sullivan Recognizes BroadReach for Improving the Health and Wellbeing of Underserved Populations
Silver Spring Emergency Physicians Join US Acute Care Solutions
Stress Light Therapy Launches Crowd-Funded Campaign on Indiegogo.com
Frost & Sullivan Names Optum 2016 North America Company of the Year for Population Health Management
R-Pharm Produces Biological Drugs in Yaroslavl with GE Healthcare's FlexFactory™ Manufacturing Platform
GE to Invest €150 Million in Biopharmaceutical Manufacturing Campus in Cork, Ireland, and Establish Advanced Manufacturing Training Centre At NIBRT
Ultimate Medical Group Announces A New Regenerative Medicine Division

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  JobsWare.com

Visit  Triggr & Bloom

Visit  BizJobs.com







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today